Effect of marine collagen peptides on markers of metabolic nuclear receptors in type 2 diabetic patients with/without hypertension

Biomedical and Environmental Sciences

Volumn 23, Issue 2, 2010, Pages 113-120

  Zhu, Cui Feng ^a,b   Li, Guan Zhi ^b   Peng, Hong Bin ^a   Zhang, Fan ^b   Chen, Yun ^b   Li, Yong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Farnesoid X receptor; Liver X receptor; Marine collagen peptide; Metabolic nuclear receptor; Peroxisome proliferator activated receptor (PPAR)

Indexed keywords

EID: 77952853495     PISSN: 08953988     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-3988(10)60040-2     Document Type: Article

References (28)

1. American Diabetes Association (2003). Treatment of Hypertension in Adults With Diabetes. Diabetes Care, pp. S80-S82.
2. Vijan S, Hayward R A (2003). Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med, pp. 593-602.
3. Grossman E, Messerli F H, Goldbourt U (2000). High blood pressure and diabetes mellitus. Are all antihypertensive drugs created equal? Arch Intern Med 160, 2447-2452.
4. Giunti S, Cooper M (2006). Management strategies for patients with hypertension and diabetes: why combination therapy is critical. J Clin Hypertens (Greenwich) pp. 108-113.
5. Duvala C, Mtlllera M and Kersten S (2007). PPARα and dyslipidemia. Biochim Biophys Acta pp. 961-971.
6. Aroda V R, Henry R R (2003). Thiazolidinediones: potential link between insulin resistance and cardiovascular disease. Diabetes Spectrum (16), 120-125.
7. Laffitte B A, Chao L C, Li J, et al. (2003). Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 100, 5419-5424.
8. Duran-Sandoval D, Mautino G, Martin G, et al. (2004). Glucose regulates the expression of the famesoid X receptor in liver. Diabetes 53, 890-898.
9. Ahmed W, Ziouzenkova O, Brown J, et al. (2007). PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med 262 (2), 184-98.
10. Aneiros A, Garateix A (2004). Bioactive peptides from marine sources: pharmacological properties and isolation procedures. J Chromatogr B Analyt Technol Biomed Life Sci 803, 41-53.
11. Chiasson J L, Josse R G, Gomis R, et al. (2003). Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-N1DDM trial. JAMA 290, 486-494.
12. QI Wen-hang, PAN Chang-yu, LIN Shan-yan (2007). A survey of factors influencing prognosis and control rate for patients with hypertension in mainland China. Zhonghua Xin Xue Guan Bing Za Zhi. 35, 457-460. (In Chinese)
13. Dong Y, Gao W, Nan H, et al. (2005). Prevalence of type 2 diabetes in urban and rural Chinese populations in Qingdao. China Diabet Med 22, 1427-33. (In Chinese)
14. Fahmi A, Morimura S, Guo H C, et al. (2004). Production of angiotensin I converting enzyme inhibitory peptides from sea bream scales. Process Biochem 39, 1195-1200.
15. Namjoshi S, Caccetta R, Benson H A (2008). Skin peptides: biological activity and therapeutic opportunities. J Pharm Sci 97 (7), 2524-2542.
16. Hiro no 1, Kondo H, Koyama T, et al. (2007). Characterization of Japanese flounder (Paralichthys olivaceus) NK-lysin, an antimicrobial peptide. Fish Shellfish Imunol 22, 567-575. (Pubitemid 46176648)
17. Morimura S, Nagata H, Uemura Y, et al. (2002). Development of an effective process for utilization of collagen from live stock and fish waste. Process Biochem 37, 1403-1412.
18. Theodore A E, Kristinsson H G (2007). Angiotensin converting enzyme inhibition of fish protein hydrolysates prepared from alkaline-aided channel catfish protein isolate. J Sci Food Agric 87 (12), 2353-2357.
19. Soydinc S, Davutoglu V, Sari I. (2007). High serum levels of adiponectin improve coronary collateral development in patients with coronary artery disease. Tohoku J Exp Med 211 (4), 347-352.
20. Wang Z, Hall S D, Maya J F, et al. (2003). Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55 (1), 77-85.
21. Doi Y, Kiyohara Y, Kubo M, et al. (2005). Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 28 (10), 2497-500.
22. Yaturu S. Bridges J F, Ready D R. (2006). Decreased levels of plasma adiponectin in prediabetes.type 2 diabetes and coronary artery disease. Med Sci Monit 12 (1), CR17-20.
23. Gloyn A L, McCarthy M I. (2008). Genetics: how the UKPDS contributed to determining the genetic landscape of Type 2 diabetes. Diabet Med 25 (Suppl 2), 35-40.
24. Havel P J (2002). Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 13 (1), 51-59.
25. Steppan CM, Bailey ST, Bhat S, et al. (2001). The hormone resistin links obesity to diabetes. Nature 409, 307-312.
26. Ishimura E, Okuno S, Kono K, et al. (2009). Glycemic control and survival of diabetic hemodialysis patients-importance of lower hemoglobin A1C levels[J]. Diabetes Res Clin Pract 83 (3), 320-326.
27. Henriksen E J, Jacob S, Fogt D L, et al. (1998). Effect of chronic bradykinin administration on insulin action in an animal model of insulin resistance. Am J Physiol 275 (1), R40-45.
28. Ylikorkala O, Viinikka L (1981). Prostaglandin and thromboxane in diabetes. Br Med J (Clin Res Ed) 283, 1148-1150.